Home  |  Contact

UniProtKB/Swiss-Prot P05155: Variant p.Val56Ala

Plasma protease C1 inhibitor
Gene: SERPING1
Variant information

Variant position:  56
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Valine (V) to Alanine (A) at position 56 (V56A, p.Val56Ala).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (V) to small size and hydrophobic (A)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism:  Chymotrypsin uses Ala-465 as its reactive site in normal plasma protease C1 inhibitor, and His-466 as its reactive site in the variant His-466.
Additional information on the polymorphism described.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  56
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  500
The length of the canonical sequence.

Location on the sequence:   SLQDRGEGKVATTVISKMLF  V EPILEVSSLPTTNSTTNSAT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SLQDRGEGKVATTVISKMLFVEPILEVSSLPTTNSTTNSAT

Mouse                         EAQAKSRESFPERDDSW----SPP-EPTVLPSTWPTTSVAI

Rat                           VVQEGSRDSVPERDGSR----SPI-EHTGQSSTWPTTSGST

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 23 – 500 Plasma protease C1 inhibitor
Glycosylation 47 – 47 O-linked (GalNAc...) threonine
Glycosylation 48 – 48 O-linked (GalNAc...) threonine
Glycosylation 64 – 64 O-linked (GalNAc...) serine
Glycosylation 69 – 69 N-linked (GlcNAc...) asparagine
Glycosylation 71 – 71 O-linked (GalNAc...) threonine


Literature citations

Normal C1 inhibitor mRNA expression level in type I hereditary angioedema patients: newly found C1 inhibitor gene mutations.
Kang H.-R.; Yim E.-Y.; Oh S.-Y.; Chang Y.-S.; Kim Y.-K.; Cho S.-H.; Min K.-U.; Kim Y.-Y.;
Allergy 61:260-264(2006)
Cited for: VARIANT HAE ARG-345; VARIANTS ALA-56 AND MET-480;

Mutational spectrum and geno-phenotype correlation in Chinese families with Hereditary Angioedema.
Xu Y.Y.; Zhi Y.X.; Yin J.; Wang L.L.; Wen L.P.; Gu J.Q.; Guan K.; Craig T.; Zhang H.Y.;
Allergy 67:1430-1436(2012)
Cited for: VARIANTS HAE ALA-118; CYS-154; PHE-170; ARG-184; PRO-230; LYS-232; ASN-272 DEL; ARG-299; GLN-430; THR-441; PRO-447; SER-466; CYS-466; LEU-466; GLY-473 AND GLY-497; VARIANTS ALA-56 AND MET-480;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.